What PSA Actually Measures
PSA — prostate-specific antigen — is a protein produced by both healthy and cancerous prostate cells. It is measured in nanograms per millilitre (ng/mL) on a standard blood test. PSA is not a cancer test in the way a biopsy is — it is a screening signal that helps your GP decide whether further investigation is warranted.
The Australian conversation around PSA has shifted significantly since 2018. The pathway no longer goes straight from "elevated PSA" to "biopsy". With multiparametric MRI now Medicare-funded for elevated PSA, and with much better understanding of the harms of over-diagnosis, around half of the biopsies that would have been performed a decade ago are now avoided.
Australian Reference Ranges (Age-Adjusted)
Unlike most blood tests, PSA does not have a single normal range — it rises naturally with age as the prostate enlarges. The thresholds below are used by RACGP, Cancer Council Australia, and the Prostate Cancer Foundation of Australia:
| Age | PSA upper limit (ng/mL) | What ''borderline'' looks like |
|---|---|---|
| 40–49 | 2.0 | 2.0–3.0 → repeat + free PSA |
| 50–59 | 2.5 | 2.5–4.0 → repeat + free PSA |
| 60–69 | 3.5 | 3.5–5.5 → repeat + free PSA + consider MRI |
| 70–79 | 4.5 | 4.5–6.5 → repeat + free PSA + MRI |
| 80+ | 6.5 | Individualised — life expectancy and patient preference matter most |
A single result above the age cut-off is not a cancer diagnosis. It triggers a repeat test in 1–3 months (with the test-day precautions described below) and, if still elevated, a free-PSA ratio plus a multiparametric MRI before any biopsy is considered.
Should You Even Get One? The Australian Position
This is the most important and most misunderstood part of the PSA conversation. The 2024 RACGP Red Book and Cancer Council Australia both take the same position:
Routine population-wide PSA screening is not recommended. Offer PSA screening to asymptomatic men aged 50–69 (or 45+ with a first-degree family history of prostate cancer) only after a shared-decision conversation that explicitly covers the benefits and harms.
The benefit: regular PSA screening modestly reduces prostate cancer mortality — roughly 1 fewer death per 1,000 men screened over 13 years (ERSPC trial data adapted to Australian population).
The harms:
- Many slow-growing prostate cancers found by PSA would never have caused symptoms in a man''s lifetime — but diagnosis triggers anxiety, biopsy procedures, and often treatment with significant side effects (urinary incontinence, erectile dysfunction).
- Around 100–120 men per 1,000 screened need a biopsy at some point. Most are negative.
- Roughly 30 men per 1,000 screened are diagnosed with prostate cancer. Of those, perhaps 5–10 had cancer that would actually have shortened their life if untreated.
The decision is personal. Family history, ethnicity (men of African ancestry have roughly twice the risk), life expectancy, and personal values all matter. Discuss with your GP — it is one conversation worth having properly rather than relying on a tick-box at a corporate health check.
What Affects PSA Accuracy
An unexpectedly high PSA is often explained by something benign and recent:
- Ejaculation within 48 hours — raises PSA by 0.5–1.0 ng/mL on average.
- Vigorous cycling or horse riding in the 24–48 hours before — direct prostate compression releases PSA.
- Urinary tract infection (current or within the past 2 weeks).
- Acute prostatitis — can raise PSA into the double digits transiently.
- Recent digital rectal examination by a doctor (within 24 hours).
- Recent urinary catheterisation or urological procedure.
- Finasteride or dutasteride (used for benign prostatic hyperplasia or hair loss) — lowers PSA by 30–50%. To estimate untreated PSA, double the result.
The RACGP recommends a 7-day window of no ejaculation, no cycling, no UTI symptoms, and no recent rectal exam before the test for the most reliable result.
The Modern Pathway After a High PSA
The Australian standard of care in 2026 looks like this:
- Repeat the PSA in 1–3 months, with all the test-day precautions above. Around 30% of mildly elevated results normalise on retest.
- If still elevated, request free PSA when total PSA is between 4.0 and 10.0 ng/mL. A free-PSA ratio >25% is reassuring; <15% raises suspicion of cancer.
- If still concerning, refer for multiparametric MRI of the prostate (mpMRI). Medicare funds this under MBS item 63541 for men with elevated PSA. The MRI is graded on a 1–5 scale (PI-RADS); scores of 1–2 usually mean no biopsy needed.
- Targeted biopsy is performed only on PI-RADS 3–5 lesions, sampling specific MRI-identified areas rather than the older "12-core blind biopsy". This pathway has roughly halved unnecessary biopsies in Australia since 2018.
What a "High" PSA Actually Means by Number
| PSA range | Likelihood of clinically significant cancer | Typical next step |
|---|---|---|
| Within age range | ~3% over the next 5 years | Routine — repeat in 2 years if shared decision favours screening |
| 1.1–2.0× age cut-off | ~10–15% | Repeat in 1–3 months |
| 2.0–3.0× age cut-off (or 4–10 ng/mL) | ~25% | Repeat + free PSA + consider MRI |
| >10 ng/mL | ~50% | MRI + urology referral |
| >20 ng/mL | >80%, often with metastasis | Urgent urology + bone scan |
Tracking PSA Over Time
The single most useful thing you can do with PSA is track its velocity — how fast it changes year to year. A PSA of 3.0 today is reassuring if last year it was 2.8, but concerning if last year it was 1.2. Australian guidelines specifically note that a PSA velocity of >0.75 ng/mL per year (or >25% increase per year) is more concerning than the absolute number.
Most Australian pathology portals only show your last 1–2 results, which makes velocity calculations impossible without manual record-keeping. Uploading every PSA report to BloodTrack graphs the velocity automatically and lets you see the long-range trend across years — exactly what your GP and urologist need to make the next decision.
Bottom Line
PSA is a screening signal, not a diagnosis. Australian guidelines recommend it only after a shared-decision conversation with your GP, and only for men aged 50–69 (or earlier with family history). A single elevated result is rarely an emergency — repeat the test, check free PSA, and let the modern MRI-first pathway prevent unnecessary biopsies.